All Oncology News

Certain factors were associated with sustained remission with obe-cel in acute lymphoblastic leukemia.

Hetty E. Carraway, MD, MBA, discusses shifting treatment paradigms in AML from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Alexander B. Olawaiye, MD, discusses key efficacy and safety findings from the ROSELLA trial and the future of relacorilant in platinum-resistant ovarian cancer.

Mayo Clinic researchers have discovered a key reason some patients with cancer relapse after receiving CAR T-cell therapy.

The FDA has received an NDA for relacorilant for the treatment of patients with platinum-resistant ovarian cancer.

The FDA received a BLA resubmission for tabelecleucel in EBV-positive post-transplant lymphoproliferative disease.

Regorafenib plus trifluridine/tipiracil was active in patients with pretreated metastatic colorectal cancer.

Pasritamig was safe and produced durable responses in heavily pretreated metastatic castration-resistant prostate cancer.

Adjuvant dalpiciclib plus endocrine therapy met the iDFS primary end point in the DAWNA-A trial in HR-positive, HER2-negative early breast cancer.

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

Breelyn Wilky, MD, discusses the importance of recognizing GIST Awareness Day and research towards moving the needle in the GIST treatment paradigm.

The FDA approves Y-90 resin microspheres in HCC, the sNDA for decitabine/cedazuridine plus venetoclax in AML is under review, and more.

Richard F. Riedel, MD, discusses the rarity of PEComa, challenges with managing this disease, and the role of sarcoma specialists in staging and treatment.

Oncology experts recap their key takeaways from the 2025 ESMO Gastrointestinal Cancers Congress.

After 3 years of follow-up, dostarlimab plus chemotherapy was effective and tolerable in patients aged 70 years or older with endometrial cancer.

Researchers found potential biomarkers that can highly predict which patients with stage III melanoma have better outcomes or are at high risk of recurrence.

The NMPA has approved lisaftoclax in adult patients with relapsed/refractory CLL/SLL.

ADRX-0405 has received orphan drug designation from the FDA for the treatment of patients with gastric cancer.

Maurie Markman, MD, raises concerns about public health priorities and resource allocation in light of the expanding role of precision medicine in cancer.

Results from the GoldiLox trial showed high complete and MRD-negative responses with glofitamab plus pirtobrutinib in covalent BTK inhibitor–exposed MCL.

The FDA has published a collection of complete response letters that were seeking the approval of drugs or biologic products between 2020 and 2024.

Treatment with HER3-DXd led to intracranial responses with a tolerable safety profile in patients with metastatic breast cancer and brain metastases.

Lydia Scarfò, MD, details the early efficacy and safety profile of BTK degrader BGB-16673 for the treatment of patients with relapsed/refractory CLL/SLL.

New research from Fox Chase Cancer Center uncovers mechanisms of breast cancer resistance to CDK4/6 inhibitors and offers innovative treatment strategies.

The combination of enzalutamide and leuprolide improved OS vs leuprolide alone in nmHSPC with high-risk biochemical recurrence at high risk for metastasis.

The European Commission has approved tislelizumab plus gemcitabine/cisplatin for adults with recurrent or metastatic nasopharyngeal carcinoma.

Kevin Kalinsky, MD, MS, FASCO, discusses the importance of optimizing endocrine-based therapies in hormone receptor–positive metastatic breast cancer.

HER2DX genomic scoring predicted pCR after neoadjuvant THP in a high-risk subgroup of patients with HER2-positive early breast cancer.

Rocío García-Carbonero, MD, discusses safety challenges in third-line mCRC and the role of molecular testing in aggressive GI neuroendocrine tumors.

Decitabine plus cedazuridine and venetoclax is under review for patients with newly diagnosed AML who are ineligible for intensive induction chemotherapy.